

Adult CIRB - Late Phase Emphasis Meeting Agenda

January 15, 2026

I Amendment

EAA181, Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase III Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation (Version Date 12/03/25)

II Continuing Review

A011801, The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSEssment to Optimize Therapy in HER2-Positive Breast Cancer): CompassHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinb (Version Date 12/03/24)

III Continuing Review

A012303, ShortStop-HER2: Shortened Duration of Adjuvant Therapy in Patients with Early-Stage HER2+ Breast Cancer Who Achieve pCR After Neoadjuvant Chemotherapy with HER2 Blockade (Version Date 06/16/25)

IV Continuing Review

A091404, A Phase II Study of Enzalutamide (NSC# 766085) for Patients with Androgen Receptor Positive Salivary Cancers (Version Date 05/20/25)

V Continuing Review

EA3132, Phase II Randomized Trial of Radiotherapy with or without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) with TP53 Sequencing (Version Date 08/14/25)

VI Continuing Review

RTOG-1216, Randomized Phase II/III Trial of Adjuvant Radiation Therapy with Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk, Squamous Cell Cancer of the Head and Neck (Version Date 03/13/25)

VII Continuing Review

EA2222, A Randomized Phase III Study of Systemic Therapy with or without Hepatic Arterial Infusion for Unresectable Colorectal Liver Metastases: The PUMP Trial (Version Date 12/19/25)

VIII Continuing Review

EA4151, A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission (Version Date 05/18/23)

IX Continuing Review

EA5231, Randomized Phase III Trial of Checkpoint Blockade in Lung Cancer Patients in the Adjuvant Setting Based on Pathologic Response Following Neoadjuvant Therapy (CLEAR) (Version Date 04/16/25)

X Continuing Review

EA6141, Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma (Version Date 07/30/25)

XI Continuing Review

NRG-GU009, Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation (PREDICT-RT) (Version Date 05/16/24)

XII Continuing Review

NRG-GU014, Randomized Phase II Trial of Pembrolizumab and Radiation vs. Radiation and Concurrent Chemotherapy for High-Grade T1 Bladder Cancer (PARRC Trial) (Version Date 04/22/25)

XIII Continuing Review

NRG-GY004, A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women with Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (Version Date 11/11/25)

XIV Continuing Review

NRG-GY024, Groningen International Study on Sentinel Nodes in Vulvar Cancer (GROINSS-V) III: A Prospective Phase II Treatment Trial (Version Date 10/19/23)

XV Continuing Review

RTOG-1308, Phase III Randomized Trial Comparing Overall Survival After Photon Versus Proton Chemoradiotherapy For Inoperable Stage II-IIIB NSCLC (Version Date 05/28/24)

XVI Continuing Review

EA9161, A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab versus Ibrutinib and Obinutuzumab in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL) (Version Date 10/31/25)

XVII Continuing Review

S1922, Randomized Phase II Selection Study of Ramucirumab and Paclitaxel Versus FOLFIRI In Refractory Small Bowel Adenocarcinoma (Version Date 03/20/23)

XVIII Continuing Review

S2000, A Randomized Phase II Trial of Encorafenib + Binimetinib + Nivolumab vs Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma with Symptomatic Brain Metastases (Version Date 08/01/25)

XIX Continuing Review

S2409, PRISM: PRecIision in SCLC via a Multicohort Study: Randomized Phase II Studies Evaluating Maintenance Durvalumab with or without Biomarker-Directed Therapy for Extensive Stage Small Cell Lung Cancer (ES-SCLC) (Version Date 04/11/25)
